The past 12 months have seen rapid innovation and transformation across the Animal Health industry. Stonehaven Cozmix Group explores advancements in technology and business models shaping the sector’s future, including
- Major launches – Spotlight on new launches in Companion Animal dermatology, cardiology, and parasiticides and Farm Animal vaccines
- Generics Landscape – Evolving competition and market dynamics
- Business Activity – Notable M&A transactions and start-up funding
- Innovative Models – Emerging business approaches reshaping customer engagement and routes to commercialisation
- AI in Animal Health – Growing applications across R&D, diagnostics, and decision-making.
Matthias Hofer
Managing Partner
Stonehaven Cozmix Group
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Chad Terrell
Head of Business Development
Stonehaven Cozmix Group
Kristin Peck
Chief Executive Officer
Zoetis
Zoetis
Website: https://www.zoetis.com/
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees.
For more information, visit www.zoetis.com
Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development
Zoetis
Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.